Discovery of the anticancer activity for lung and gastric cancer of a brominated coelenteramine analog

Abstract

Cancer is still a challenging disease to treat, both in terms of harmful side effects and therapeutic efficiency of the available treatments. Herein, to develop new therapeutic molecules, we have investigated the anticancer activity of halogenated derivatives of different components of the bioluminescent system of marine Coelenterazine: Coelenterazine (<b>Clz</b>) itself, Coelenteramide (<b>Clmd</b>), and Coelenteramine (<b>Clm</b>). We have found that <b>Clz</b> derivatives possess variable anticancer activity toward gastric and lung cancer. Interestingly, we also found that both brominated <b>Clmd</b> (<b>Br-Clmd</b>) and <b>Clm</b> (<b>Br-Clm</b>) were the most potent anticancer compounds toward these cell lines, with this being the first report of the anticancer potential of these types of molecules. Interestingly, <b>Br-Clm</b> possessed some safety profile towards noncancer cells. Further evaluation revealed that the latter compound induced cell death via apoptosis, with evidence for crosstalk between intrinsic and extrinsic pathways. Finally, a thorough exploration of the chemical space of the studied <b>Br-Clm</b> helped identify the structural features responsible for its observed anticancer activity. In conclusion, a new type of compounds with anticancer activity toward gastric and lung cancer was reported and characterized, which showed interesting properties to be considered as a starting point for future optimizations towards obtaining suitable chemotherapeutic agents.